{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"18.7","value":"14.4"},{"comment":"\\<75% of participants experienced the event within the treatment arm. Hence, third-quartile could not be derived.","groupId":"OG001","lowerLimit":"8.4","upperLimit":"NA","value":"21.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"}],"units":"Participants"}],"description":"DoR per RECIST v1.1 was defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. CR is defined as disappearance of all target lesions. Any pathological lymph nodes must be \\<10 millimeters (mm) in the short axis. PR is defined as at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the Baseline sum diameters.","dispersionType":"Inter-Quartile Range","groups":[{"description":"Participants with Ovarian Cancer (OC) received recommended phase 2 dose (RP2D) of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG000","title":"Phase 2 OC: Niraparib 200 mg + Pembrolizumab"},{"description":"Participants with Triple Negative Breast Cancer (TNBC) received RP2D of Niraparib 200 mg orally once daily and Pembrolizumab 200 mg IV on Day 1 of each 21-day cycle.","id":"OG001","title":"Phase 2 TNBC: Niraparib 200 mg + Pembrolizumab"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set. Only those participants with data available at specified time point were analyzed.","reportingStatus":"POSTED","timeFrame":"Up to a maximum of 54 months","title":"Phase 2: Duration of Response (DOR) as Measured by RECIST v1.1","type":"SECONDARY","unitOfMeasure":"Months"}